AZN vs. NVO
Compare and contrast key facts about AstraZeneca PLC (AZN) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AZN or NVO.
Correlation
The correlation between AZN and NVO is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
AZN vs. NVO - Performance Comparison
Loading data...
Key characteristics
AZN:
-0.38
NVO:
-1.19
AZN:
-0.36
NVO:
-1.80
AZN:
0.95
NVO:
0.77
AZN:
-0.32
NVO:
-0.85
AZN:
-0.56
NVO:
-1.55
AZN:
15.80%
NVO:
32.60%
AZN:
23.25%
NVO:
42.63%
AZN:
-48.94%
NVO:
-71.29%
AZN:
-20.37%
NVO:
-55.31%
Fundamentals
AZN:
$210.70B
NVO:
$288.38B
AZN:
$2.49
NVO:
$3.52
AZN:
27.29
NVO:
18.79
AZN:
0.91
NVO:
1.00
AZN:
3.83
NVO:
0.95
AZN:
5.13
NVO:
14.15
AZN:
$54.98B
NVO:
$303.14B
AZN:
$44.75B
NVO:
$255.65B
AZN:
$17.70B
NVO:
$154.08B
Returns By Period
In the year-to-date period, AZN achieves a 6.49% return, which is significantly higher than NVO's -23.96% return. Both investments have delivered pretty close results over the past 10 years, with AZN having a 10.61% annualized return and NVO not far ahead at 10.67%.
AZN
6.49%
2.62%
10.35%
-8.87%
7.66%
10.61%
NVO
-23.96%
2.37%
-35.71%
-50.65%
16.98%
10.67%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AZN vs. NVO — Risk-Adjusted Performance Rank
AZN
NVO
AZN vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
AZN vs. NVO - Dividend Comparison
AZN's dividend yield for the trailing twelve months is around 2.22%, less than NVO's 2.50% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 2.22% | 2.27% | 2.15% | 2.14% | 2.40% | 2.80% | 2.81% | 3.61% | 3.95% | 5.01% | 4.06% | 3.98% |
NVO Novo Nordisk A/S | 2.50% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Drawdowns
AZN vs. NVO - Drawdown Comparison
The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum NVO drawdown of -71.29%. Use the drawdown chart below to compare losses from any high point for AZN and NVO. For additional features, visit the drawdowns tool.
Loading data...
Volatility
AZN vs. NVO - Volatility Comparison
The current volatility for AstraZeneca PLC (AZN) is 8.42%, while Novo Nordisk A/S (NVO) has a volatility of 14.83%. This indicates that AZN experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
AZN vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between AstraZeneca PLC and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AZN vs. NVO - Profitability Comparison
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, AstraZeneca PLC reported a gross profit of 11.35B and revenue of 13.59B. Therefore, the gross margin over that period was 83.5%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a gross profit of 65.20B and revenue of 78.09B. Therefore, the gross margin over that period was 83.5%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, AstraZeneca PLC reported an operating income of 3.67B and revenue of 13.59B, resulting in an operating margin of 27.0%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported an operating income of 38.79B and revenue of 78.09B, resulting in an operating margin of 49.7%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, AstraZeneca PLC reported a net income of 2.92B and revenue of 13.59B, resulting in a net margin of 21.5%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a net income of 29.03B and revenue of 78.09B, resulting in a net margin of 37.2%.